14-day Premium Trial Subscription Try For FreeTry Free
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of BCRX
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Red day on Thursday for BioCryst Pharmaceuticals
(Updated on Apr 25, 2024)

Sell candidate since Apr 12, 2024 Loss -12.79% PDF

The BioCryst Pharmaceuticals stock price fell by -1.19% on the last day (Thursday, 25th Apr 2024) from $4.21 to $4.16. It has now fallen 10 days in a row. During the last trading day the stock fluctuated 3.47% from a day low at $4.03 to a day high of $4.17. The price has fallen in 10 of the last 10 days and is down by -18.43% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -1 million shares and in total, 3 million shares were bought and sold for approximately $10.96 million.

The stock has broken the wide and falling short-term trend down. Firstly a stronger fallrate is indicated, but false breaks and "sell-off" may occur. However, a further fall is realistic and any reactions back to the breaking point ($4.30) are considered to be a "second chance" to get out. According to the fan-theory $3.69 will represent the new bottom line of the next trend, but it is far too early to say this for certain.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

BCRX Signals & Forecast

There are few to no technical positive signals at the moment. The BioCryst Pharmaceuticals stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $4.38 and $4.87. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, April 11, 2024, and so far it has fallen -18.43%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss for BioCryst Pharmaceuticals stock

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.140 between high and low, or 3.47%. For the last week, the stock has had daily average volatility of 5.35%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (BCRX) For The Upcoming Trading Day Of Friday 26th

For the upcoming trading day on Friday, 26th we expect BioCryst Pharmaceuticals to open at $4.12, and during the day (based on 14 day Average True Range), to move between $3.90 and $4.42, which gives a possible trading interval of +/-$0.259 (+/-6.23%) up or down from last closing price. If BioCryst Pharmaceuticals takes out the full calculated possible swing range there will be an estimated 12.45% move between the lowest and the highest trading price during the day.

With no support below and resistance from accumulated volume @ $5.00, some $0.84 (20.19%) from the current price of $4.16, our system finds the risk reward not very attractive.

Is BioCryst Pharmaceuticals stock A Buy?

BioCryst Pharmaceuticals holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -7.612 Strong Sell Candidate Unchanged

Predicted Opening Price for BioCryst Pharmaceuticals of Friday, April 26, 2024

Fair opening price April 26, 2024 Current price
$4.12 ( 0.96%) $4.16

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for BCRX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 4.26 2.40 %
R2 4.21 1.12 %
R1 4.17 0.324 %
Current price: 4.16
Support S1 4.07 -2.25 %
S2 4.03 -3.04 %
S3 3.98 -4.33 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 5.14 23.56 %
R2 5.08 22.12 %
R1 5.00 20.19 %
Current price 4.16
Support S1 0 .
S2 0 .
S3 0 .

FAQ

What is the symbol for BioCryst Pharmaceuticals Stock and on which exchange is it traded?
The symbol for BioCryst Pharmaceuticals is BCRX and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell BioCryst Pharmaceuticals Stock?
BioCryst Pharmaceuticals holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy BioCryst Pharmaceuticals Stock?
BioCryst Pharmaceuticals Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy BioCryst Pharmaceuticals Stock.

What's the current price of BioCryst Pharmaceuticals Stock?
As of the end of day on the Apr 25, 2024, the price of an BioCryst Pharmaceuticals (BCRX) share was $4.16.

What is the 52-week high and low for BioCryst Pharmaceuticals Stock?
The 52-week high for BioCryst Pharmaceuticals Stock is $9.07 and the 52-week low is $4.03.

What is the market capitalization of BioCryst Pharmaceuticals Stock?
As of the Apr 25, 2024, the market capitalization of BioCryst Pharmaceuticals is 857.584M.

When is the next earnings date for BioCryst Pharmaceuticals?
The upcoming earnings date for BioCryst Pharmaceuticals is May 06, 2024.
Click to get the best stock tips daily for free!

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II... BCRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT